KMT2A / MLLT1 t(11;19) Fusion probe hybridized to patient material showing t(11;19) translocation (2RG1R1G).
KMT2A / MLLT1 t(11;19) Fusion probe hybridized to patient material showing t(11;19) translocation (2RG1R1G).
IVD KMT2A/MLLT1
One of the relatively frequently observed translocations (around 10 %) in AML and ALL involves the genes KMT2A (previously known as MLL) and MLLT1 (aka ENL) at 11q23 and 19p13. The KMT2A/MLLT1 translocation results in the generation of fusion protein that retains the MLL N-terminus, including both an A-T hook domain and a region similar to mammalian DNA methyltransferase. There are several breakpoints within the MLLT1 gene described, without clear differences in clinicohematologic features. The KMT2A/MLLT1 Fusion probe is optimized to detect translocations involving the KMT2A and MLLT1 gene regions at 11q23 and 19p13 in a dual-color, fusion assay on metaphase/interphase spreads, blood smears and bone marrow cells in a dual-color, fusion assay.
References: Mitterbauer-Hohdanner G et al, 2004, Eur J Clin Invest, 34; 12-24. Meyer C et al, 2009, Leukemia, 23; 1490-1499. Fu JF et al, 2007, Am J Clin Pathol, 127; 24-30.
Produkte
Produkte
KBI-10307
KMT2A/MLLT1 t(11;19) Fusion
Product is out of stock
Due to manufacturing & supply chain issues, this product is currently unavailable. You may place your order and it will be fulfilled when the product is back in stock. For more help, please reach out to customer service at +1 844 534 2262 or nonurgentcs@leicabiosystems.com
Product is limited in stock
Product availability is limited, but products are in continuous production. Your order will be processed as normal and may take additional days to ship.